Drug intelligence / Profile preview

AEX-1

Development stage: Preclinical
Lead developer: Aexon Labs
Modality: Small Molecules

Overview

AEX-1 is a small molecule drug candidate developed by Aexon Labs for the treatment of Alzheimer's disease. It features a multi-target mechanism of action, functioning as a Sigma-1 receptor (S1R) agonist, a Cathepsin H (CTSH) inhibitor, and an Orexin receptor 1 (OX1R) agonist. This polypharmacological approach is designed to address complex pathological features of Alzheimer's, including tau protein abnormalities, neuroinflammation, and synaptic dysfunction. By targeting S1R, the molecule aims to provide neuroprotection and improve protein homeostasis, while its activity on CTSH and OX1R is intended to further modulate inflammatory responses and support neuronal health. AEX-1 is currently in the discovery stage of development.

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)HCRTR1 (Orexin/hypocretin receptor type 1)CTSH (Cathepsin H)

Beyond the preview

Go deeper on AEX-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEX-1.

Explore the full profile